Integrilin

Eptifibatide, the active ingredient in Integrilin, is a Glycoprotein IIb/IIIa inhibitor presented as an intravenous solution for intravenous use. It prevents platelet aggregation and is used to reduce cardiac ischemic complications in patients undergoing percutaneous coronary intervention or experiencing acute coronary syndrome.

GNH USA supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Integrilin (eptifibatide) is employed as an antiplatelet agent in the management of acute coronary syndromes and related interventional procedures. - Unstable angina: reduces risk of myocardial infarction and death during percutaneous coronary intervention. - Non‑ST‑elevation myocardial infarction (NSTEMI): helps prevent further ischemic events when used with PCI. - Acute coronary syndrome (ACS): provides rapid platelet inhibition to limit thrombus formation. - Percutaneous coronary intervention (PCI): maintains vessel patency by inhibiting platelet aggregation during the procedure.

Eptifibatide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bleeding at catheter insertion site. - Thrombocytopenia. - Hypotension. - Nausea. - Headache. - Fever.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Severe allergic reactions (anaphylaxis). - Myocardial infarction. - Life‑threatening thrombosis. - Immune‑mediated thrombocytopenia. - Death.

When using Integrilin, clinicians should consider several safety measures. - Renal impairment: adjust infusion rate and monitor renal function. - Recent surgery or trauma: assess bleeding risk before administration. - Concomitant anticoagulants: increase monitoring for bleeding. - History of thrombocytopenia: avoid or use with caution. - Pregnancy and lactation: use only if benefits outweigh risks (category unknown). - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Eptifibatide can interact with other agents that affect haemostasis.

Major Interactions (Avoid): - Heparin: additive anticoagulant effect, risk of severe bleeding. - Other Glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban): combined platelet inhibition may cause life‑threatening hemorrhage. - Thrombolytics (alteplase, reteplase): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Warfarin: increased INR, monitor coagulation parameters. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency. - CYP450 substrates: minimal interaction but monitor if co‑administered with drugs affecting platelet function.